Research Article

Upregulation of lnc-ZNF281 Inhibits the Progression of Glioma via the AKT/GSK-3β/β-Catenin Signaling Pathway

Figure 6

Increased β-catenin reversed the suppressive effects of lnc-ZNF281 on glioma cells. (a–c) β-catenin agonist SKL2001 was used to upregulate β-catenin expression, and the Western blot results showed that SKL2001 significantly increased the protein expression levels of β-catenin. (d, e) The CCK-8 assay results indicated that β-catenin reversed the inhibitory effects of lnc-ZNF281 on the proliferation of glioma cells. (f, g) The transwell assay results indicated that β-catenin reversed the inhibitory effects of lnc-ZNF281 on the migration of glioma cells. μm. .
(a)
(b)
(c)
(d)
(e)
(f)
(g)